CGAS and cancer: Furthermore, the appropriate activation of the cGAS–STING pathway in immune cells provides beneficial effects that can restrain tumor growth, whereas the persistent activation of this pathway may contribute to the formation of carcinogen-induced tumors and arrest the development of T cell-driven adaptive immunity [198]; thus, examining the context of the cancer conditions is crucial in determining the applicability of the cGAS–STING pathway agonists in cancer immunotherapy.